Live Quote · NASDAQVCREHealthcare· Medical - Pharmaceuticals

Vicore Pharma Holding AB

$13.78▼ 0.97%($-0.14)
TickerSpark Score

Limited financial coverage for VCRE.

Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.

30
Momentum
52-Week Range15% of range
Low
$13.09
Current
$13.78
High
$17.80
Company Overviewvicorepharma.com

About the company

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.

CEO
Ahmed Mousa
IPO
2026
Employees
37
HQ
Solna, US
Performance & Tape
52W High
$17.80
52W Low
$13.09
50D MA
$14.84
200D MA
$14.84
Beta
0.15
Avg Volume
203.13K

Get TickerSpark's AI analysis on VCRE

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Coverage · VCRE

Our VCRE coverage

Recent articles, reports, and earnings notes.

View all →
Should You Buy the Vicore Pharma Holding AB IPO? Here's the Setup
IPO

Should You Buy the Vicore Pharma Holding AB IPO? Here's the Setup

Vicore Pharma Holding AB American Depositary Shares are expected to list on NASDAQ on 2026-07-02, with the price range not disclosed yet. This is a U.S. dual listing, not a traditional cash-raising IPO, so the main question is whether the story around buloxibutid is strong enough to attract U.S. investors. The bull case is a first-in-class IPF drug in a large unmet market; the bear case is a clinical-stage company still years from commercialization.

Jul 23 MIN
For Active Investors

Want a deeper read on VCRE?

Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.

Generate VCRE report →